)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Aligos Therapeutics (ALGS) investor relations material
Aligos Therapeutics H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 27th Annual Global Investment Conference summary5 Sep, 2025
Pipeline and scientific innovation
Advanced a potent capsid assembly modulator, ALG-000184, for HBV, showing high oral bioavailability and strong liver exposure.
Demonstrated dual mechanism: blocks HBV pgRNA encapsulation and CCC DNA replenishment, leading to significant reductions in viral antigens and DNA.
No resistance observed in 96-week phase 1B data, supporting monotherapy potential and regulatory pathway.
Phase 2B B Supreme study designed to show superiority over standard of care, with endpoints focused on HBV DNA suppression and antigen reduction.
Paired biopsies in phase 2B will assess integration and CCC DNA reduction, aiming for comprehensive disease control.
Regulatory and clinical development
Regulatory agencies accept chronic suppression (HBV DNA below 10 IU) as an approvable endpoint for monotherapy.
ALG-000184 achieved 100% suppression in E negative and 60–100% in E positive patients at 48–96 weeks, outperforming nucleoside analogs.
Success in B Supreme defined by DNA suppression and antigen reduction, with potential to become new standard of care.
Ongoing studies include direct comparison to standard therapies and integration with functional cure regimens.
Commercial and strategic outlook
Chronic suppressive therapy remains essential for over 90% of HBV patients, as most do not qualify for functional cure regimens.
ALG-000184 positioned as both standard of care for suppression and backbone for future cure combinations.
Company developing its own antisense oligonucleotide (ASO) program, aiming for superior combination regimens.
Significant global unmet need in HBV and MASH, with multibillion dollar market potential.
How does 184's resistance profile enable monotherapy?
How does 184 complement ASO therapies for HBV cure?
What differentiates 055009 for MASH partnerships?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Aligos Therapeutics earnings date
H.C. Wainwright Liver Disease Virtual Conference21 Oct, 2025
Next Aligos Therapeutics earnings date
H.C. Wainwright Liver Disease Virtual Conference21 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Aligos Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel therapeutics to address unmet medical needs in viral and liver diseases. The company's development pipeline includes drug candidates for the treatment of conditions such as non-alcoholic steatohepatitis (NASH), chronic hepatitis B (CHB), and coronavirus. Aligos Therapeutics utilizes a combination of small molecule and oligonucleotide platforms to create pharmacologically optimized drug candidates aimed at improving treatment outcomes in these diseases. The company is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage